Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-10-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2018年第三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2018 年第三季度报告' which translates to '2018 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period ending September 30, 2018. The report is unaudited as stated in the text. The content includes comprehensive financial statements and management discussion of financial results for a period shorter than a full fiscal year (quarterly report). This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. 9M 2018
2018-10-29 Chinese
第九届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the approval of the company's 2018 third quarter report and an accounting policy change. It mentions the review and approval of the 2018 Q3 report but does not contain the report itself, only a statement that the full report is available on the Shanghai Stock Exchange website. The document is short (1074 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the financial report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement related to regulatory compliance and internal governance but does not contain substantive financial data or the full report text.
2018-10-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about a change in accounting policies. It details the specific changes in financial statement presentation according to new accounting standards issued by the Ministry of Finance, including changes to balance sheet and income statement line items. The document includes no actual financial statements or comprehensive financial data but rather explains the nature and impact of the accounting policy change. It also includes opinions from independent directors and the supervisory board endorsing the change. The document length is under 5,000 characters and is primarily an announcement of a policy change rather than a full financial report. Therefore, it does not qualify as an Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is not a regulatory certification or officer attestation, so it is not Regulatory Filings (RNS). The best fit is a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes that do not constitute a full financial report or audit report.
2018-10-29 Chinese
关于控股股东股票质押式回购交易调整购回交易日的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding adjustments to the repurchase transaction date of pledged shares by its controlling shareholder. It details the number of shares pledged, the adjustment of the repurchase date, and the purpose and risks associated with the pledge. The document is short (1040 characters) and focuses on share pledge and repurchase transaction updates, not on financial results, management changes, or legal proceedings. It does not contain financial statements or detailed financial data. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock pledges and repurchase transactions.
2018-10-26 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company 中源协和细胞基因工程股份有限公司 regarding the progress of the transfer of 67% equity in 浙江赛尚医药科技有限公司. It details the background of the equity transfer agreement, payment delays, breach of contract, and the initiation of legal proceedings. The document does not contain financial statements or detailed financial data but is an update on a specific transaction and related legal action. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate event and legal matter, not a full report or financial statement.
2018-10-26 Chinese
关于控股股东部分股权补充质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the supplementary pledge of shares by its controlling shareholder. It details the number of shares pledged, the pledgees, the purpose of the pledge, and risk management measures. The document is short (1022 characters) and focuses on share pledge information, which relates to changes in shareholding or capital structure but does not announce new share issuance or capital changes per se. It is not a full financial report, earnings release, or management report. It is also not a voting result or AGM material. The content fits best with a Share Issue/Capital Change announcement or a Major Shareholding Notification. However, since it concerns pledge of shares (a form of capital structure change) rather than ownership threshold crossing, the best fit is Share Issue/Capital Change (SHA).
2018-10-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.